Sociedad Americana de Hirudoterapia

Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties.

Review published in Cellular and molecular life sciences : CMLS (1997)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosFarmacología salivalHall et al. · Cellular and molecular life sciences : CMLS, 1997

Abstract

Thrombin is a serine proteinase that can interact with a large number of diverse macromolecular substrates, which results in either a procoagulant or anticoagulant effect. These divergent properties are physiologically regulated by the endogenous protein thrombomodulin. This review summarizes recent work on a variety of methods used to exploit the allosteric nature of the enzyme. The procoagulant and anticoagulant functions of thrombin can be modulated by sodium binding, site-directed mutagenesis, and a small synthetic molecule. Modulation of thrombin's intrinsic properties represents a novel approach to the development of unique antithrombotic agents.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAllosteric RegulationAnimalsAnticoagulantsAntithrombin IIIAntithrombinsFibrinolytic AgentsHumansProtein ConformationProtein EngineeringStructure-Activity RelationshipThrombinThrombomodulin

Resumen

Thrombin is a serine proteinase that can interact with a large number of diverse macromolecular substrates, which results in either a procoagulant or anticoagulant effect. These divergent properties are physiologically regulated by the endogenous protein thrombomodulin.

Por qué esto importa para la hirudoterapia

This review discusses strategies for developing novel antithrombotic agents by exploiting thrombin's allosteric regulation, noting that thrombin's procoagulant and anticoagulant functions are physiologically regulated by thrombomodulin and can be modulated by sodium binding, site-directed mutagenesis, and a small synthetic molecule. It frames modulation of thrombin's intrinsic properties as a novel antithrombotic approach. The abstract does not mention hirudin, leeches, leech-derived compounds, or hirudotherapy, so it offers no direct evidence for ASH's domain. Any connection to leech-based therapeutics would be speculative and outside the abstract's stated content.

Citación

Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties.

Hall et al. · Cellular and molecular life sciences : CMLS, 1997

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsSalivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexHirudinAnticoagulation CompoundsHemostasisOtolaryngologyPost-Thrombotic Syndrome

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.